ACIU - AC Immune SA
IEX Last Trade
2.7
0.010 0.370%
Share volume: 1,743
Last Updated: Thu 26 Dec 2024 08:29:36 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$2.69
0.01
0.37%
Fundamental analysis
21%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
15%
Performance
5 Days
0 0%
1 Month
-21.18%
3 Months
-27.57%
6 Months
-32.49%
1 Year
-43.46%
2 Year
53.58%
Key data
Stock price
$2.70
DAY RANGE
$2.62 - $2.71
52 WEEK RANGE
$2.39 - $5.04
52 WEEK CHANGE
-$44.63
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/01/2024
Company detail
CEO: Andrea Pfeifer
Region: US
Website: acimmune.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: acimmune.com
Employees: 140
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
AC Immune SA discovers, designs, and develops medicines and diagnostic products. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease. It is also developing ACI-24, an anti-Abeta vaccine candidate, as well as completed Phase Ib clinical study for Down syndrome. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases.
Recent news